Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress

Adaptive Biotechnologies (ADPT) announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma and chronic lymphocytic leukemia. “The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development,” said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. “These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma anticipated at the 18th International Conference on Malignant Lymphoma on June 17-21, 2025 in Lugano, Switzerland.”